At a Glance
- Market value: USD 1,140 million (2025)
- Forecast value: USD 1,955 million (2031)
- Forecast CAGR: 9.41% (2025-2031)
- Dominant region: South India
- Dominant segment: Infectious Disease Rapid Tests
- Total number of players: 85
What Is Changing in the India POCT Market?
The India POCT Market is projected to expand from USD 1,140 million in 2025 to USD 1,955 million by 2031, reflecting a robust 9.41% forecast CAGR. This acceleration outpaces the historical 7.34% CAGR recorded between 2020 and 2025 and is anchored by four inter‑related forces: recurring consumables such as strips and cartridges, the rollout of decentralized molecular assay platforms, higher‑value cardiac and coagulation panels, and a surge in self‑testing options. Public primary‑care infrastructure, exemplified by 1,81,873 operational Ayushman Arogya Mandirs and 41.93 crore cumulative teleconsultations by November 2025, is widening the testing funnel beyond metropolitan hospitals to rural community health centres.
Test volume is expected to climb from 815 million equivalents in 2025 to roughly 1,280 million equivalents by 2031, while the blended value per test rises as molecular, immunofluorescence and connected‑analyzer formats capture greater share. Glucose monitoring remains the largest recurring pool, yet infectious‑disease rapid tests and cardiometabolic panels are slated to deliver the strongest incremental revenue streams. The market’s evolution is also reflected in the connected analyzer base, which is forecast to grow from 62,000 units in 2025 to 130,000 units by 2031, reinforcing data traceability and integration with the national health‑record ecosystem.
Why Is Recurring Consumables and Decentralized Molecular Assays Important for the India POCT Market?
Impact on Market Demand
Recurring consumables create a predictable revenue engine because high‑frequency screening for glucose, HbA1c, lipids and cardiovascular markers drives repeat purchases. The National NCD Portal’s enrollment of 74.97 crore beneficiaries by December 2025 has generated a broad, continuously refreshed demand pool for near‑patient testing. This demand is amplified in hospital and diagnostic clusters across Maharashtra, Karnataka, Tamil Nadu, Telangana, Delhi NCR and Gujarat, where clinicians rely on rapid, point‑of‑care results to initiate same‑visit treatment decisions.
Decentralized molecular assays add a premium layer to demand by enabling near‑patient detection of infectious agents without the need for centralized laboratory infrastructure. As the report notes, the shift toward molecular, immunofluorescence and connected analyzer formats is a key driver of the projected 7.82% volume CAGR, indicating that clinicians are increasingly willing to adopt higher‑complexity tests at the point of care when supported by reliable consumable supply chains.
Impact on Competition
Domestic manufacturers can capture value by localizing reagent and cartridge production, thereby improving gross margins and enhancing competitiveness in public tenders. The report highlights a 34% domestic value addition in 2025, supported by the medical‑device PLI programme’s commissioning of 19 greenfield projects and the enablement of 44 previously imported products by September 2024. This creates a fertile ground for Indian firms to challenge multinational incumbents on price and supply reliability.
Multinational suppliers, however, retain strategic advantages in assay breadth, quality management systems and integration with hospital information systems. Their established assay menus and connectivity solutions position them to serve higher‑value cardiac and coagulation panels, where clinical workflows demand seamless data exchange and regulatory compliance.
Impact on Market Growth
The convergence of recurring consumable pull‑through and decentralized molecular capabilities underpins the 9.41% forecast CAGR. As test volumes rise, the blended value per test improves, delivering a dual engine of volume‑driven and margin‑driven growth. Public procurement expansion, especially through Ayushman Arogya Mandirs, adds a stable, government‑backed demand source that mitigates cyclicality and supports long‑term market scaling.
Nevertheless, the report flags execution risks that could temper growth: price compression pressures, the need for robust operator training, and stringent lot‑to‑lot quality control. Companies that proactively address these challenges are likely to secure a larger share of the expanding market.
What Does the Ken Research Report Reveal About Market Opportunities?
Largest Product Segment: Glucose Monitoring Products
Glucose monitoring remains the largest recurring consumable pool, driven by the massive diabetic population and the National NCD Portal’s enrollment figures. The high‑frequency nature of glucose testing ensures a steady consumable turnover, making it a cornerstone for revenue stability.
Fastest Growing Segment: Infectious Disease Rapid Tests
Infectious disease rapid tests are identified as the dominant segment and the fastest‑growing product type. The post‑pandemic environment has heightened awareness of rapid diagnostics, and public health initiatives continue to prioritize infectious‑disease screening at community health centres.
Technology Opportunity: Connected Analyzer Base
The connected analyzer base is projected to double from 62,000 units in 2025 to 130,000 units by 2031. This growth unlocks opportunities for software‑enabled services, remote monitoring, and integration with the ABDM dashboard, which already links more than 95 crore health records.
Regional Opportunity: South India Dominance
South India emerges as the dominant region, reflecting a dense network of hospitals, diagnostic labs, and a strong public‑sector presence. Companies targeting this geography can leverage existing infrastructure and a receptive regulatory environment to accelerate market penetration.
Channel Opportunity: Public Primary‑Care Procurement
With 1,81,873 Ayushman Arogya Mandirs operational by November 2025 and a cumulative footfall of 494.71 crore, public primary‑care sites constitute a nationally distributed testing channel. Tender participation and localized reagent production can enhance competitiveness in this expanding channel.
What Does the Market Shift Mean for Businesses?
Aftermarket and Recurring Revenue Opportunities
Interpretation: The report suggests that firms focusing on consumable‑led business models—especially strips, cartridges and reagents—stand to benefit from the repeat‑purchase dynamics inherent in high‑frequency glucose and infectious‑disease testing. Rental or lease‑to‑own models for analyzers, combined with reagent‑supply contracts, can generate stable, long‑term cash flows.
Interpretation: Domestic manufacturers that secure public‑sector contracts for localized reagents can capture margin uplift while supporting government goals of self‑reliance. The 34% domestic value addition figure underscores the financial upside of local production.
Market Adoption and Execution Challenges
Interpretation: Price compression remains a salient risk, particularly as public tenders drive down unit costs. Companies must balance cost competitiveness with quality assurance to avoid lot‑to‑lot variability that could erode clinician confidence.
Interpretation: Operator training and quality‑control frameworks are critical for sustaining adoption across decentralized sites. Investment in training programs and robust quality‑management systems will be essential to meet the execution standards highlighted in the report.
What Should India POCT Market Participants Watch Next?
- Increasing price compression in public tenders and its impact on margin structures
- Scaling operator training programs to ensure consistent test quality across rural and urban sites
- Lot‑to‑lot quality control mechanisms as a safeguard against assay variability
- Expansion of home‑testing and self‑monitoring solutions driven by consumer demand
- Integration of test results with digital health records via the ABDM dashboard
- Regulatory developments affecting domestic reagent manufacturing and device approvals
Conclusion: India POCT Market Outlook
The India POCT Market is poised to reach USD 1,955 million by 2031, propelled by a 9.41% CAGR, expanding test volumes, and a shift toward consumable‑centric, connected diagnostic platforms. While domestic manufacturers can leverage localization and public‑sector procurement, multinational players will continue to dominate high‑value assay segments. Success will hinge on navigating price pressures, ensuring operator competence, and maintaining stringent quality controls across an increasingly decentralized testing landscape.
